Corcept Therapeutics Incorporated (HTD.F)
| Previous Close | 20.39 |
| Open | 20.48 |
| Bid | 21.39 x 63700 |
| Ask | 21.80 x 61200 |
| Day's Range | 20.48 - 20.48 |
| 52 Week Range | 19.40 - 31.60 |
| Volume | |
| Avg. Volume | 19 |
| Market Cap | 2.165B |
| Beta (5Y Monthly) | 0.48 |
| PE Ratio (TTM) | 23.27 |
| EPS (TTM) | 0.88 |
| Earnings Date | May 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.25 |
GlobeNewswireCorcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 1, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a u
ZacksCorcept (CORT) Posts Positive Data From Cushing's Syndrome Study
Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.
GlobeNewswireCorcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
MENLO PARK, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol, today announced positive results from the open-label portion of the pivotal Phase 3 GRACE trial of its proprietary selective cortisol modulator relacorilant in patients with all etio
